Clinical trials: Optic Atrophy
Geographic Atrophy
A Study to Test Different Doses of BI 1584862 in People With a Distinct Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy
This study is open to adults aged 50 years and older with geographic atrophy that was diagnosed by imaging of the retina. The purpose of this study is to find out whether a medicine called BI 1584862 improves the eyes in people…
- Trial name
- NCT06769048
- Testing
- BI 1584862
- Where
- 44 sites in United States, Puerto Rico
- Volunteers
- 150 people
- Sponsor
- Boehringer Ingelheim
Leber Hereditary Optic Neuropathy
Trial of Cyclosporine in the Acute Phase of Leber Hereditary Optic Neuropathy
The Leber Hereditary Optic Neuropathy is a genetic disorder caused by maternal transmission of mitochondrial DesoxiroboNucleid Acid mutations.
- Trial name
- CICLO-NOHL (NCT02176733)
- Testing
- cyclosporine
- Where
- France
- Volunteers
- 12 people
- Sponsor
- University Hospital, Angers
Wolfram Syndrome 1, Optic Atrophies, Hereditary
Does Recessive Optic Atrophy Due to WFS1 Exist?
All patients with Wolfram syndrome and recessive optic atrophy due to a mutation of the WFS1 from a single Center were included in a retrospective study.
- Trial name
- NCT07336966
- Testing
- analyse study
- Volunteers
- 45 people
- Sponsor
- Hôpital Necker-Enfants Malades
Gestational Diabetes Mellitus in Pregnancy
Impact of DHA/Oat on Metabolic Health in Gestational Diabetes Mellitus
The randomized controlled trial (RCT) recruits pregnant women with de novo diagnosis of gestational diabetes. Women bearing a singleton pregnancy are randomized into four arms: DHA, oat, oat plus DHA, and placebo.
- Trial name
- NCT03569501
- Testing
- DHA, oat grains
- Where
- China
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Leber Hereditary Optic Neuropathy (Optic, Atrophy, Hereditary, Leber)
EAP_GS010_single Patient
Expanded Access Use for a single patient of Bilateral Intravitreal Injection of GS010 in a Single Subject Affected with G11778A ND4 Leber Hereditary Optic Neuropathy
- Trial name
- NCT03672968
- Testing
- GS010
- Sponsor
- GenSight Biologics
Leber Congenital Amaurosis 10, Blindness
Study to Evaluate Sepofarsen in Subjects With Leber Congenital Amaurosis (LCA) Type 10 (HYPERION)
The purpose of this double-masked, randomized, placebo-controlled, paired-eye study is to evaluate the efficacy, safety and tolerability of Sepofarsen in subjects with Leber Congenital Amaurosis (LCA) due to the c.2991+1655A>G…
- Conditions
- Leber Congenital Amaurosis 10, Blindness, Leber Congenital Amaurosis, Sensation Disorders
- Trial name
- HYPERION (NCT06891443)
- Testing
- sepofarsen
- Where
- 18 sites in United States, Australia and 8 more
- Volunteers
- 32 people
- Sponsor
- Laboratoires Thea
Geographic Atrophy
A Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration
This is a 24-month, Phase III, multicenter, randomized, double-masked, sham-injection controlled study to assess the efficacy and safety of multiple IVT injections of APL-2 in subjects with GA secondary to AMD.
- Trial name
- NCT03525613
- Testing
- APL-2
- Where
- 112 sites in United States, Australia and 12 more
- Volunteers
- 637 people
- Sponsor
- Apellis Pharmaceuticals, Inc.
Geographic Atrophy, Age-Related Macular Degeneration
A Study About the Safety of ASP3021 Eye Injections and if They Help People in Japan With Vision Loss From Age-related Macular Degeneration
Age-related macular degeneration (AMD) is an eye disease which causes people to lose their vision over time. AMD damages the macula, which is in the middle of the retina - the light sensitive part at the back of the eye.
- Trial name
- NCT06970665
- Testing
- avacincaptad pegol
- Where
- 11 sites in Japan
- Volunteers
- 17 people
- Sponsor
- Astellas Pharma Inc
Geographic Atrophy
Geographic Atrophy Long-Terms Outcomes Study
The purpose of this study is to describe functional and long-term clinical outcomes of patients with a diagnosis of Geographic Athrophy secondary to Age related Macular Degenaration in Clinical Practice
- Trial name
- GALTOS (NCT06499571)
- Where
- 5 sites in Australia, France and 3 more
- Volunteers
- 255 people
- Sponsor
- Apellis Pharmaceuticals, Inc.
Gastritis, Atrophic, Helicobacter Pylori Infection
Diagnosis of Gastritis, H. Pylori Infection and Atrophic Gastritis in Dyspeptic Patients
Gastric cancer is the third most common cause of cancer-related death worldwide (1). Upper endoscopy is necessary to detect neoplastic macroscopic features at an early stage, but subtle abnormalities in the gastric mucosa are…
- Conditions
- Gastritis, Atrophic, Helicobacter Pylori Infection, Intestinal Metaplasia, Gastritis
- Trial name
- NCT04296513
- Testing
- High-Definition white light endoscopy., High-definition magnification with digital chromoendoscopy.
- Where
- Ecuador
- Volunteers
- 150 people
- Sponsor
- Instituto Ecuatoriano de Enfermedades Digestivas
Optic Pathway Glioma
Safety and Efficacy of the PAINLESS Nerve Growth Factor CHF6467 in Optic Pathway Glioma (OPG)
Infantile optic pathway glioma (OPG) is generally benign and slow-growing, but due to infiltration and compression of sensitive neuronal structures in the optical pathways, progressive visual loss is a frequent and highly…
- Trial name
- NGF-OPG (NCT05733572)
- Testing
- CHF6467
- Where
- Italy
- Volunteers
- 36 people
- Sponsor
- Benedetto Falsini
Geographic Atrophy, Macular Degeneration
A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
The purpose of this study is to assess the long-term safety and tolerability after an intravitreal injection (a shot of medicine into the eye) of JNJ-81201887 administered in parent clinical studies.
- Trial name
- NCT06635148
- Testing
- JNJ-81201887
- Where
- 104 sites in United States, Australia and 16 more
- Volunteers
- 274 people
- Sponsor
- Janssen Research & Development, LLC
Geographic Atrophy
A Multicenter, Proof-Of-Concept Study Of Intravitreal AL-78898A In Patients With Geographic Atrophy (GA) Associated With Age-Related Macular Degeneration (AMD)
The purpose of this study was to to demonstrate superiority of AL-78898A intravitreal (IVT) injections compared to sham injections by assessing mean geographic atrophy (GA) lesion size change from baseline at Month 12.
- Trial name
- NCT01603043
- Testing
- Al-78898A
- Volunteers
- 10 people
- Sponsor
- Alcon Research
Geographic Atrophy
Phase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Geographic Atrophy
This Phase 3, multicenter, double-masked, parallel-group, placebo-controlled, randomized, fixed-dose clinical study is designed to evaluate the efficacy and safety of tinlarebant (LBS-008) in subjects diagnosed with GA.
- Trial name
- PHOENIX (NCT05949593)
- Testing
- Tinlarebant
- Where
- 49 sites in United States, Australia and 6 more
- Volunteers
- 429 people
- Sponsor
- Belite Bio, Inc
Geographic Atrophy
An Extension Study to Evaluate the Long-Term Safety of Lampalizumab in Participants With Geographic Atrophy
This is a multicenter, open-label extension study of safety and tolerability of lampalizumab administered by intravitreal (ITV) injection to participants with geographic atrophy (GA) who have completed the 18-month treatment in…
- Trial name
- NCT01602120
- Testing
- Lampalizumab
- Where
- 46 sites in United States, Germany
- Volunteers
- 159 people
- Sponsor
- Genentech, Inc.
Geographic Atrophy (GA)
Intravitreal (IVT) Pozelimab for Geographic Atrophy (GA) in Adult Participants
This study is researching an experimental drug called pozelimab (called "study drug"). The study is focused on people with a condition where certain parts of the eye's retina stop working over time, which can make it harder to…
- Trial name
- VIENNA (NCT07230834)
- Testing
- Pozelimab
- Where
- 9 sites in United States, Georgia and 2 more
- Volunteers
- 54 people
- Sponsor
- Regeneron Pharmaceuticals
Dry Age-related Macular Degeneration, Geographic Atrophy
First in Human Study to Evaluate the Safety and Tolerability of GEM103 in Geographic Atrophy Secondary to Dry Age Related Macular Degeneration
The study is designed to identify the maximum tolerated dose (MTD) for intravitreal (IVT) administration of GEM103 in subjects with geographic atrophy (GA) secondary to dry AMD.
- Conditions
- Dry Age-related Macular Degeneration, Geographic Atrophy, Macular Degeneration, Retinal Disease
- Trial name
- NCT04246866
- Testing
- GEM103
- Where
- 12 sites in United States
- Volunteers
- 12 people
- Sponsor
- Gemini Therapeutics, Inc.
Vision Disorders
Optical Coherence Tomography Measurements in Eyes With Band Atrophy
The study is designed to evaluate the ability of optical coherence tomography and VCC scanning laser polarimetry to measure and identify the pattern of band atrophy of the optic nerve in patients with long standing chiasmal…
- Trial name
- NCT00395122
- Testing
- Retinal nerve fiber layer and macular thickness measurements
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University of Sao Paulo
Wolfram Syndrome, Diabetes Mellitus
A Clinical Trial of Dantrolene Sodium in Pediatric and Adult Patients With Wolfram Syndrome
Wolfram syndrome is a rare genetic disorder characterized by juvenile-onset diabetes mellitus, diabetes insipidus, optic nerve atrophy, hearing loss, and neurodegeneration.
- Conditions
- Wolfram Syndrome, Diabetes Mellitus, Optic Nerve Atrophy, Ataxia
- Trial name
- NCT02829268
- Testing
- dantrolene sodium
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Washington University School of Medicine
Parkinsonian Syndrome, Parkinson Disease(PD)
A Study to Evaluate the Diagnostic Efficacy of DaTSCAN™ Ioflupane (123I) Injection in Single Photon Emission Computed Tomography (SPECT) for the Diagnosis of Parkinsonian Syndrome (PS) in Chinese Patients
This is a multicenter, open-label, non-controlled, non-randomized, phase 3 clinical study to compare the SPECT findings after a single IV administration of DaTSCAN™ ioflupane (123I) injection for patients with a clinical…
- Conditions
- Parkinsonian Syndrome, Parkinson Disease(PD), Multiple System Atrophy (MSA), Progressive Supranuclear Palsy (PSP)
- Trial name
- NCT04193527
- Testing
- DaTSCAN™ Ioflupane (123I) Injection
- Where
- 10 sites in China
- Volunteers
- 172 people, healthy volunteers welcome
- Sponsor
- GE Healthcare